Manchester Blood Test Speeds ROS1 Lung Cancer Matching to Tablet Therapy
A grandmother with stage four lung cancer is now receiving treatment in tablet form after a blood test revealed a genetic change that opened the door to targeted therapy. For Christina Isik, 71, the finding changed the practical shape of care: instead of conventional chemotherapy, clinicians identified a ROS1 mutation and moved to a drug designed to slow the cancer’s growth and potentially halt its spread.
The case captures a wider shift in oncology. Blood-based genomic testing is no longer confined to specialist centres abroad or to long waits that delay treatment decisions. In Manchester, a laboratory now handles these samples for the whole of the north of England, cutting the turnaround time from six weeks to 14 days.
A Genetic Result That Changed the Treatment Path
Christina fell ill while on holiday in Turkey two years ago and later received her diagnosis after returning home for medical care. At The Christie in Manchester, clinicians did not simply move straight to chemotherapy. They sent a blood sample for genetic sequencing, looking for a molecular driver that could be matched to a more precise treatment.
That search uncovered the ROS1 mutation. In lung cancer, this matters because a mutation can act as a dominant growth signal, allowing the tumour to be attacked with a drug built to interfere with that specific pathway rather than exposing the entire body to broad cytotoxic therapy. The logic is straightforward and biologically elegant: if the tumour depends on a particular abnormal signal, suppressing that signal can produce more durable control with less collateral damage than a blanket approach.
Christina’s experience also illustrates why molecular testing has become central to modern oncology rather than an optional extra. For a patient facing stage four disease, a result that converts treatment from infusion-based chemotherapy to oral targeted therapy can alter daily life, toxicity burden, and the sense of control over the illness.
One blood tube can now redirect the entire treatment plan.
Why the Manchester Hub Matters for Access and Timing
Until late last year, samples from the north of England had to be sent to Germany for analysis. That international pathway stretched waiting time to six weeks, a long interval for patients with advanced cancer, where delays can affect symptom progression and the urgency of treatment selection. The North West Genomic Laboratory Hub, located opposite Manchester Royal Infirmary, now manages the testing locally.
The laboratory’s Scientific Operational Director, Dr Emma Howard, said staff traveled to Germany to learn the complex testing process before bringing it home. The result is not just administrative convenience. Shorter turnaround creates a tighter clinical loop between diagnosis, molecular profiling, and treatment initiation, which is especially important in advanced disease where each week can feel clinically consequential.
The test itself, developed by Roche, examines fragments of DNA that detach from the tumour and circulate in the bloodstream. These fragments, often referred to in clinical practice as circulating tumor DNA, can carry the cancer-driving alterations clinicians need in order to match a patient to therapy. The technical challenge is considerable: the abnormal gene must be detected among thousands of other genetic signals in the sample.
Targeted Therapy Is Expanding Beyond Breast and Lung Cancer
At present, the Manchester lab can identify faulty genes for breast and lung cancer, but expansion is already under way. The same testing platform is now being used for cancers of unknown primary, where the origin of the malignancy cannot be identified easily. Discussions are also under way around biliary cancers, pancreatic cancer, and potentially prostate cancer, with clinical trial opportunities for patients also being considered.
This is where the value of genomic testing becomes broader than one diagnosis. The assay is not tied to a single tumour type; it is built to detect actionable changes across cancers, which is why it can travel into other disease areas once the laboratory workflow is validated. In practical terms, the test can turn a generic cancer label into a biologically specific treatment plan.
Dr Matthew Krebs, consultant in medical oncology at The Christie, described personalized treatment as focusing on the part of the cancer that is actually driving the problem. His point reflects a central principle of precision oncology: when the molecular driver is known, the treatment strategy can be narrowed to the biology of the disease rather than using therapy that attacks rapidly dividing cells indiscriminately.
What Tablet Treatment Means for a Patient With Advanced Disease
For Christina, the treatment shift has a human meaning that goes beyond laboratory precision. She has spoken about looking forward to enjoying life, seeing her two young grandchildren grow up, and being present for her son’s wedding in 2028. Those plans sit beside the medical reality of stage four lung cancer, but they are not abstract wishes; they are shaped by the fact that her disease is now being controlled through a molecular target rather than treated with chemotherapy alone.
Targeted therapy can offer fewer side effects than conventional treatment, and in some cancers it can work more effectively when a clearly defined mutation is present. The key is eligibility. Not every tumour carries an actionable mutation, and not every patient will qualify for a targeted medicine. Even so, the expansion of local genomic testing means more patients can reach that decision point without the delays created by overseas referral.
The broader clinical message is direct. Molecular testing is moving closer to routine care, and when the result is fast enough, it can change both the medicine chosen and the time at which treatment begins. For patients with advanced lung cancer, that difference may determine whether therapy feels reactive and generalized or precise and biologically informed.
The next challenge is scale. More cancer types may soon be added, but the test will only matter if eligible patients are identified early enough to benefit from it and if the molecular findings can be translated into access to the right drug without delay.